29 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
15 Oct 14
Regulation FD Disclosure
12:00am
Momentum
Healthy volunteer data
at ASH 2014
Initiate Ph 2 in PK
deficiency patients by
early 2015
AG -
Remaining 2014 Potential Product Milestones … patient blood
ex vivo
A suite of biomarkers have been implemented in our healthy volunteer
trials and will be included in patient trials
This is very
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
7 Aug 14
Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results
12:00am
in second half of 2014; abstract of additional Phase 1 data submitted to the 2014 ASH Annual Meeting -
- AG-348: Phase 1 healthy volunteer studies … announced today in the Phase 1 healthy volunteer studies, the company believes it will be in a position to initiate a Phase 2 clinical trial for AG-348
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
7 Nov 14
Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
12:00am
. In addition, we look forward to presenting the first clinical data for AG-348 from the healthy volunteer studies at the American Society of Hematology (ASH … to present the first clinical data from healthy volunteer studies with AG-348 in a poster presentation at the ASH Annual Meeting in December. Key results
DEFA14A
AGIO
Agios Pharmaceuticals Inc
12 Jan 21
Additional proxy soliciting materials
5:15pm
. The NDA will be filed this year in the first half of this year. And we’ll be looking at the data from our healthy volunteer study for our next … , I’ve talked about Mitapivat already, and then this year we look forward to presenting data from our healthy volunteer study for AG946 and then talking
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
5 May 22
Agios Reports Business Highlights and First Quarter 2022 Financial Results
7:21am
Deficiency Program –
– Completed Healthy Volunteer Cohorts and Initiated Sickle Cell Disease Cohort of AG-946 Phase 1 Study; On Track to Initiate … transfusions in the New England Journal of Medicine.
Completed the single ascending dose and multiple ascending dose healthy volunteer cohorts of the Phase
8-K
EX-99.1
li9l44owfi r5
17 Apr 14
Other Events
12:00am
8-K
EX-99.1
yoqdb 71q6hiuaj6n
2 Apr 21
Agios Announces Closing of Oncology Business Sale to Servier
4:47pm
8-K
EX-99.1
t95irip6ltke99iq1
16 Oct 15
Regulation FD Disclosure
12:00am
8-K
EX-99.3
ysvwa
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.1
576j6 h44bos
29 Jul 21
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
7:17am
8-K
EX-99.1
om9gnxrz
3 Nov 21
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
7:27am
8-K
EX-99.1
5cpuzj4ma7n79 ltv1
24 Feb 22
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
7:40am
DEFA14A
EX-99.2
s0vw0nr nm
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.2
q8h46bvyu9uxtd6yi1x
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.1
9v343msbv3a4cwpk
13 Jan 14
Regulation FD Disclosure
12:00am
DEFA14A
90qksr6parv21s
21 Dec 20
Additional proxy soliciting materials
5:23pm
8-K
EX-99.2
rvlpfm8z
4 May 18
Results of Operations and Financial Condition
7:07am